Dentsply Sirona Inc. · NASDAQ:XRAY
Dentsply Sirona — Q1 2026 Earnings Presentation
18 slides from Dentsply Sirona's earnings presentation, May 5, 2026
Slide 1: First Quarter 2026 Earnings Conference Call
First Quarter 2026 May 5, 2026 Earnings Conference Call
Slide 2: Forward-Looking Statements and Associated Risks
Forward-Looking Statements and Associated Risks All statements in this Presentation that do not directly and exclusively relate to historical facts constitute "forward-looking statements." Such statements are subject to numerous assumptions, risks, uncertainties and other factors that could cause ac
Slide 3: Key Developments
Key Developments Transitioned into execution of Return-to-Growth Action Plan Launched Smart View–Detect, the world’s first FDA-cleared, AI- enabled diagnostic aid designed to identify teeth with periapical radiolucencies (PARL) in CBCT scans, plus CE-marked Continued to penetrate connected technolog
Slide 4: First Quarter 2026 Financial Summary
First Quarter 2026 Financial Summary Commentary Q1 2026 Q1 2025 YoY ▪ Net sales +0.1% YoY ▪ Increases in CTS and Wellspect offset by declines in EDS and OIS Net Sales $880M $879M 0.1% ▪ Constant currency revenue down (6.7%), including (2.2%) impact for Byte and one- Constant time institutional insta
Slide 5: First Quarter 2026 Segment Results
First Quarter 2026 Segment Results As Constant Net Sales Commentary Reported Currency Connected ▪ CAD/CAM: Growth in APAC, offset by lower sales in EMEA Technology Solutions $246M 4.4% (2.9%) ▪ Equipment & Instruments: Primarily driven by tough comparable (CTS) (+DD Q1 2025) with Treatment Center in
Slide 6: Maintaining 2026 Outlook
Maintaining 2026 Outlook* Net Sales $3.5B to $3.6B Operational Growth (3%) to (1%) Adjusted EPS $1.40 to $1.50 Operational growth represents change in expected FY2026 net sales in constant currency when compared to FY2025, excluding net sales attributable to Byte and the anticipated impact of the ne
Slide 7: Expanding Workflow Capabilities with Product Innovation
Expanding Workflow Capabilities with Product Innovation DS Core Endo CTS Wellspect ▪ Smart View – Detect, ▪ Reciproc Minima file ▪ A-Dec Midwest ▪ Surity female world’s first FDA- system enables the Controller streamlines external catheter cleared, AI-enabled preparation of a workflow across launche
Slide 8: Return-to-Growth Action Plan
Return-to-Growth Action Plan 1 2 3 4 5 Customer-Centric Reigniting Empowering Scaling Financial Strength Mindset Sustainable Growth Performance Organization • Establishing strategic • Driving U.S. turnaround • Transformation • Executing on • Retired approximately KOL Advisory Board to while investin
Slide 9: In Summary
In Summary “ Executing on Return-to-Growth Action Plan Expanding market access for connected technology solutions products Reallocating savings into innovation, clinical education, and sales team training Implementing new capital allocation strategy and improving working capital 9
Slide 10: Appendix
Appendix Dentsply S Sirona
Slide 11: Non-GAAP Financial Measures Definitions
Non-GAAP Financial Measures Definitions Constant Currency Adjusted Gross Profit and Margin Reported net sales adjusted for the impact of foreign currency changes, which is Gross profit excluding the impact of any of the above adjustments that affect either calculated by translating current period ne
Slide 12: Trailing Nine Quarters
Trailing Nine Quarters In millions (except percentages) Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Net Sales $953 $984 $951 $905 $879 $936 $904 $961 $880 Adjusted EBITDA $160 $173 $170 $128 $168 $197 $167 $135 $129 Adj. EBITDA Margin % 16.8% 17.5% 17.9% 14.2% 19.0% 21.1% 18.4% 14.1% 14.7%
Slide 13: Net Sales as Reported and in Constant Currency
Net Sales as Reported and in Constant Currency Q1 2026 and Q1 2025: (unaudited) 13
Slide 14: Reconciliation of Non-GAAP Financial Measures
Reconciliation of Non-GAAP Financial Measures Condensed Consolidated Statements of Operations Q1 2026 (unaudited) 14
Slide 15: Reconciliation of Non-GAAP Financial Measures
Reconciliation of Non-GAAP Financial Measures Condensed Consolidated Statements of Operations Q1 2025 (unaudited) 15
Slide 16: Reconciliation of Non-GAAP Financial Measures
Reconciliation of Non-GAAP Financial Measures Adjusted EBITDA (unaudited) 16
Slide 17: Reconciliation of Non-GAAP Financial Measures
Reconciliation of Non-GAAP Financial Measures Free Cash Flow (unaudited) 17
Slide 18: Slide 18